Skip to main content

Amy E DeZern

Jun 30, 2026

15:06
What about you, Dr. DeZern?
15:08
I agree with everything that you've mentioned.
15:11
And I think it is tricky as someone who sees mostly second opinions.
15:16
Sometimes I feel we're always on the bookends of that, not letting a therapy be tried long enough at optimal dosing or waiting so long past the point of efficacy that the patient's extremely deconditioned or very advanced by the time they seek out alternative therapies.
15:35
And I think it's because in a busy clinical practice, it's not always easy to obtain repeat bone marrow assessments or perhaps if they're receiving growth factors, they're going along and not always seeing the provider.
15:50
It flows through simply through the order sets and things like that.
15:54
And so things get a little complicated.
18:41
When you get those patients referred to you, Dr. DeZern, and not from Dr. DeStefano, from others, what kind of information might get lost in that handoff?

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.